$SMLR
Semler Scientific, Inc.

2021 Form 10-K Financial Statement

#000155485922000008 Filed on March 04, 2022

View on sec.gov

Income Statement

Concept 2021 2020 Q4 2020
Revenue $53.03M $12.07M $38.60M
YoY Change 37.36% 31.93% 17.81%
Cost Of Revenue $6.122M $986.0K $3.356M
YoY Change 82.42% 8.83% -8.33%
Gross Profit $46.91M $11.09M $35.25M
YoY Change 33.08% 34.47% 21.1%
Gross Profit Margin 88.45% 91.83% 91.31%
Selling, General & Admin $23.68M $4.431M $16.35M
YoY Change 44.85% -1.42% 2.69%
% of Gross Profit 50.49% 39.97% 46.38%
Research & Development $3.780M $660.0K $2.938M
YoY Change 28.66% -5.98% 18.52%
% of Gross Profit 8.06% 5.95% 8.34%
Depreciation & Amortization $628.0K $164.0K $138.0K
YoY Change 355.07% 1.23% -7.38%
% of Gross Profit 1.34% 1.48% 0.39%
Operating Expenses $23.68M $5.092M $16.35M
YoY Change 44.85% -2.02% 2.69%
Operating Profit $19.45M $5.995M $15.96M
YoY Change 21.83% 96.69% 49.06%
Interest Expense $10.00K $14.00K $19.00K
YoY Change -47.37% 600.0% 850.0%
% of Operating Profit 0.05% 0.23% 0.12%
Other Income/Expense, Net $10.00K $442.0K $525.0K
YoY Change -98.1% -7466.67% -7600.0%
Pretax Income $19.46M $6.451M $16.49M
YoY Change 18.01% 111.93% 54.06%
Income Tax $2.233M $1.058M $2.479M
% Of Pretax Income 11.48% 16.4% 15.04%
Net Earnings $17.22M $5.393M $14.01M
YoY Change 22.95% 90.36% -7.14%
Net Earnings / Revenue 32.48% 44.67% 36.28%
Basic Earnings Per Share $2.56 $2.13
Diluted Earnings Per Share $2.12 $663.7K $1.74
COMMON SHARES
Basic Shares Outstanding 6.732M 6.658M 6.584M
Diluted Shares Outstanding 8.139M 8.067M

Balance Sheet

Concept 2021 2020 Q4 2020
SHORT-TERM ASSETS
Cash & Short-Term Investments $37.32M $22.08M $22.08M
YoY Change 69.04% 185.22% 185.22%
Cash & Equivalents $22.08M
Short-Term Investments
Other Short-Term Assets $4.044M $1.376M $1.376M
YoY Change 193.9% 537.04% 537.04%
Inventory $550.0K $340.0K $340.0K
Prepaid Expenses $828.0K
Receivables $3.619M $2.808M $2.808M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $45.54M $26.60M $26.60M
YoY Change 71.17% 132.48% 132.48%
LONG-TERM ASSETS
Property, Plant & Equipment $2.351M $261.0K $2.202M
YoY Change 6.77% 4.82% -5.41%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $821.0K $3.051M $3.051M
YoY Change -73.09%
Other Assets $1.964M $418.0K $2.783M
YoY Change -29.43% 2686.67% -38.37%
Total Long-Term Assets $5.136M $8.036M $8.036M
YoY Change -36.09% 17.42% 17.42%
TOTAL ASSETS
Total Short-Term Assets $45.54M $26.60M $26.60M
Total Long-Term Assets $5.136M $8.036M $8.036M
Total Assets $50.67M $34.64M $34.64M
YoY Change 46.29% 89.42% 89.42%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $443.0K $677.0K $677.0K
YoY Change -34.56% 100.3% 100.3%
Accrued Expenses $3.516M $2.798M $2.873M
YoY Change 22.38% -28.51% -26.6%
Deferred Revenue $963.0K
YoY Change 0.84%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.880M $4.514M $4.514M
YoY Change 8.11% -13.31% -13.31%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $245.0K $332.0K $332.0K
YoY Change -26.2% 4642.86% 4642.86%
Total Long-Term Liabilities $245.0K $332.0K $332.0K
YoY Change -26.2% 4642.86% 4642.86%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.880M $4.514M $4.514M
Total Long-Term Liabilities $245.0K $332.0K $332.0K
Total Liabilities $5.125M $4.846M $4.846M
YoY Change 5.76% -7.06% -7.06%
SHAREHOLDERS EQUITY
Retained Earnings $7.673M
YoY Change -221.14%
Common Stock $7.000K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares $25.00K
Shareholders Equity $45.55M $29.79M $29.79M
YoY Change
Total Liabilities & Shareholders Equity $50.67M $34.64M $34.64M
YoY Change 46.29% 89.42% 89.42%

Cashflow Statement

Concept 2021 2020 Q4 2020
OPERATING ACTIVITIES
Net Income $17.22M $5.393M $14.01M
YoY Change 22.95% 90.36% -7.14%
Depreciation, Depletion And Amortization $628.0K $164.0K $138.0K
YoY Change 355.07% 1.23% -7.38%
Cash From Operating Activities $16.06M $5.514M $15.11M
YoY Change 6.23% 51.69% 18.75%
INVESTING ACTIVITIES
Capital Expenditures $318.0K -$436.0K $149.0K
YoY Change 113.42% -11.02% -14.37%
Acquisitions
YoY Change
Other Investing Activities $0.00 $152.0K -$248.0K
YoY Change -100.0%
Cash From Investing Activities -$825.0K -$284.0K -$1.006M
YoY Change -17.99% -42.04% -40.75%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 13.00K 56.00K 230.0K
YoY Change -94.35% -101.42% -103.5%
NET CHANGE
Cash From Operating Activities 16.06M 5.514M 15.11M
Cash From Investing Activities -825.0K -284.0K -1.006M
Cash From Financing Activities 13.00K 56.00K 230.0K
Net Change In Cash 15.24M 5.286M 14.34M
YoY Change 6.32% -759.93% 221.7%
FREE CASH FLOW
Cash From Operating Activities $16.06M $5.514M $15.11M
Capital Expenditures $318.0K -$436.0K $149.0K
Free Cash Flow $15.74M $5.950M $14.97M
YoY Change 5.17% 44.24% 19.21%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
605000
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001554859
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4044000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
0
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021Q4 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent
CY2021Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent
CY2021Q4 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
0
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
001-36305
CY2021 dei Entity Registrant Name
EntityRegistrantName
SEMLER SCIENTIFIC, INC.
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-1367393
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
2340-2348 Walsh Avenue, Suite 2344
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
Santa Clara
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
95051
CY2021 dei City Area Code
CityAreaCode
877
CY2021 dei Local Phone Number
LocalPhoneNumber
774-4211
CY2021 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
CY2021 dei Trading Symbol
TradingSymbol
SMLR
CY2021 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Public Float
EntityPublicFloat
471533909
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
6779058
CY2021 dei Auditor Firm
AuditorFirmId
243
CY2021 dei Auditor Name
AuditorName
BDO USA, LLP
CY2021 dei Auditor Location
AuditorLocation
New York, NY
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
37323000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22079000
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
61000
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
61000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3619000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2808000
CY2021Q4 us-gaap Inventory Net
InventoryNet
550000
CY2020Q4 us-gaap Inventory Net
InventoryNet
340000
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
963000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
80000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1376000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
45536000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
26603000
CY2021Q4 us-gaap Property Subject To Or Available For Operating Lease Net
PropertySubjectToOrAvailableForOperatingLeaseNet
1643000
CY2020Q4 us-gaap Property Subject To Or Available For Operating Lease Net
PropertySubjectToOrAvailableForOperatingLeaseNet
1941000
CY2021Q4 us-gaap Property Plant And Equipment Excluding Lessor Asset Under Operating Lease After Accumulated Depreciation
PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAfterAccumulatedDepreciation
394000
CY2020Q4 us-gaap Property Plant And Equipment Excluding Lessor Asset Under Operating Lease After Accumulated Depreciation
PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAfterAccumulatedDepreciation
261000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
332000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
418000
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
76000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4880000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4514000
CY2021Q4 us-gaap Long Term Investments
LongTermInvestments
821000
CY2020Q4 us-gaap Long Term Investments
LongTermInvestments
3051000
CY2021Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
1946000
CY2020Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
2365000
CY2021Q4 us-gaap Assets
Assets
50672000
CY2020Q4 us-gaap Assets
Assets
34639000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
443000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
677000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3436000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2798000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
921000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
245000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
332000
CY2021Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
245000
CY2020Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
332000
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6824380
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6725422
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6758458
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6700422
CY2021Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
65922
CY2020Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
25000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
7000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
7000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
20645000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
22113000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
24895000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
7673000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
45547000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
29793000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
50672000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
34639000
CY2021 us-gaap Revenues
Revenues
53027000
CY2020 us-gaap Revenues
Revenues
38603000
CY2021 us-gaap Cost Of Revenue
CostOfRevenue
6122000
CY2020 us-gaap Cost Of Revenue
CostOfRevenue
3356000
CY2021 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
3780000
CY2020 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
2938000
CY2021 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
14445000
CY2020 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
9942000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9235000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6406000
CY2021 us-gaap Costs And Expenses
CostsAndExpenses
33582000
CY2020 us-gaap Costs And Expenses
CostsAndExpenses
22642000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
19445000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
15961000
CY2021 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
10000
CY2020 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
19000
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
506000
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
10000
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
525000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
19455000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
16486000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2233000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2479000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
17222000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
14007000
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.56
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.13
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6731693
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6584441
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.12
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.74
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8138608
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8066561
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
13073000
CY2020 smlr Adjustments To Additional Capital Investment In Equity Securities
AdjustmentsToAdditionalCapitalInvestmentInEquitySecurities
2230000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
230000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
253000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
14007000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
29793000
CY2021 smlr Exercise Of Put Option In Private Company Value
ExerciseOfPutOptionInPrivateCompanyValue
2230000
CY2021 us-gaap Stock Issued During Period Value Employee Stock Ownership Plan
StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
512000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
58000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
192000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
17222000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
45547000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
17222000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
14007000
CY2021 us-gaap Depreciation And Amortization
DepreciationAndAmortization
628000
CY2020 us-gaap Depreciation And Amortization
DepreciationAndAmortization
576000
CY2021 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
408000
CY2020 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
2136000
CY2021 us-gaap Gain Loss On Sale Of Leased Assets Net Operating Leases
GainLossOnSaleOfLeasedAssetsNetOperatingLeases
-362000
CY2020 us-gaap Gain Loss On Sale Of Leased Assets Net Operating Leases
GainLossOnSaleOfLeasedAssetsNetOperatingLeases
-271000
CY2021 us-gaap Inventory Write Down
InventoryWriteDown
1202000
CY2021 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
63000
CY2020 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
55000
CY2020 smlr Non Cash Interest Income From Equity Securities
NonCashInterestIncomeFromEquitySecurities
12000
CY2020 us-gaap Debt And Equity Securities Gain Loss
DebtAndEquitySecuritiesGainLoss
442000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
749000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
253000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
318000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
149000
CY2020 smlr Payment For Long Term Note Receivable From Private Company Two
PaymentForLongTermNoteReceivableFromPrivateCompanyTwo
457000
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
874000
CY2020 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-623000
CY2021 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1412000
CY2020 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
303000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2657000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1160000
CY2021 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-86000
CY2020 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
403000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-234000
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
339000
CY2021 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
638000
CY2020 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1235000
CY2021 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-125000
CY2020 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
409000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
16056000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
15114000
CY2020 smlr Payment For Convertible Promissory Note Receivable From Private Company Three
PaymentForConvertiblePromissoryNoteReceivableFromPrivateCompanyThree
59000
CY2020 smlr Purchase Of Shares Of Preferred Stock From Private Company Three
PurchaseOfSharesOfPreferredStockFromPrivateCompanyThree
250000
CY2020 smlr Payment For Long Term Note Receivable From Private Company Three
PaymentForLongTermNoteReceivableFromPrivateCompanyThree
1424000
CY2020 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
1942000
CY2021 us-gaap Payments To Acquire Equipment On Lease
PaymentsToAcquireEquipmentOnLease
507000
CY2020 us-gaap Payments To Acquire Equipment On Lease
PaymentsToAcquireEquipmentOnLease
609000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-825000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1006000
CY2021 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
45000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
58000
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
230000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
13000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
230000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
15244000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
14338000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
22079000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7741000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
37323000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
22079000
CY2021 us-gaap Income Taxes Paid
IncomeTaxesPaid
2647000
CY2020 us-gaap Income Taxes Paid
IncomeTaxesPaid
285000
CY2020 smlr Long Term Note Receivable From Private Company Two Settled By Stock Issuance
LongTermNoteReceivableFromPrivateCompanyTwoSettledByStockIssuance
512000
CY2020 smlr Exchange Of Common Stock For Preferred Stock
ExchangeOfCommonStockForPreferredStock
2230000
CY2021 smlr Investment In Private Company Number Of Shares Purchased
InvestmentInPrivateCompanyNumberOfSharesPurchased
211928
CY2021 smlr Exercise Of Put Option In Private Company Shares
ExerciseOfPutOptionInPrivateCompanyShares
40922
CY2021 smlr Exercise Of Put Option In Private Company Value
ExerciseOfPutOptionInPrivateCompanyValue
2230000
CY2020 smlr Long Term Note Receivable From Private Company Three Settled By Stock Issuance
LongTermNoteReceivableFromPrivateCompanyThreeSettledByStockIssuance
59000
CY2021 us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.    The Company</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">Semler Scientific, Inc. (the “Company”) was incorporated in the State of Oregon on August 9, 2007, established C-corporation status in 2012, and reincorporated as a Delaware corporation during 2013. The Company provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers. In 2011, the Company began commercializing its first patented and U.S. Food and Drug Administration (“FDA”) cleared product, which measured arterial blood flow in the extremities to aid in the diagnosis of peripheral arterial disease (“PAD”). In March 2015, the Company received FDA 510(k) clearance for the next generation version of its product, QuantaFlo</span><sup style="font-size:5.62pt;line-height:100%;top:0pt;vertical-align:top;">®</sup><span style="font-size:10pt;">, which the Company commercially launched in August 2015. The Company has one operating segment and generates revenues domestically primarily through direct licensing to direct customers. The Company is based in Santa Clara, California.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On January 30, 2020, the World Health Organization (“WHO”) declared the recent novel coronavirus (COVID-19) outbreak a global health emergency, which prompted national, state and local governments to begin putting actions in place to slow the spread of COVID-19. In March 2020, the WHO classified the COVID-19 outbreak as a pandemic. The outbreak of COVID-19 resulted in travel restrictions, quarantines, “stay-at-home” and “shelter-in-place” orders and extended shutdown of certain businesses around the world and restricted the Company’s ability to perform in person demonstrations to potential customers and attend in-person trade shows or conduct other in-person sales activities. While restrictions began to ease in the second quarter and activities began to resume, recent outbreaks could lead to restrictions being reimplemented. In the first half of 2020, the Company’s revenues, primarily from variable-fee licenses, were negatively impacted by the COVID-19 pandemic. In the third and fourth quarters of 2020, the Company’s revenues, primarily from variable-fee licenses, rebounded to and even exceeded pre-COVID-19 levels. However, the Company believes that it possibly experienced some negative effects from the COVID-19 pandemic, with travel restrictions still in place through early 2021, and with the outbreak of the Delta and Omicron variants during the second half of 2021, which may have impacted the sequential growth of the Company’s revenues, in particular, revenue from variable-fee licenses. The extent and duration of the pandemic is unknown, and the future effects on the Company’s business are uncertain and difficult to predict. The Company is continuing to monitor the events and circumstances surrounding the COVID-19 pandemic, which may require adjustments to the Company’s estimates and assumptions in the future.</p>
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of the accompanying financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities at the date of the financial statements, and reported amounts of revenues and expenses, and related disclosures during the reporting period. Significant items subject to such estimates include revenue recognition, allowance for doubtful accounts, valuation of equipment on lease, recognition and measurement of current and deferred income taxes, valuation and recognition of investments and valuation of inventory. These estimates and assumptions are based on management’s best estimates and judgment. Management regularly evaluates its estimates and assumptions using historical experience and other factors; however, actual results could differ significantly from these estimates.</p>
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2021Q4 us-gaap Lease Practical Expedient Lessor Single Lease Component
LeasePracticalExpedientLessorSingleLeaseComponent
true
CY2021 us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
30561000
CY2020 us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
25743000
CY2021Q4 us-gaap Property Subject To Or Available For Operating Lease Gross
PropertySubjectToOrAvailableForOperatingLeaseGross
3241000
CY2020Q4 us-gaap Property Subject To Or Available For Operating Lease Gross
PropertySubjectToOrAvailableForOperatingLeaseGross
3407000
CY2021Q4 us-gaap Property Subject To Or Available For Operating Lease Accumulated Depreciation
PropertySubjectToOrAvailableForOperatingLeaseAccumulatedDepreciation
1598000
CY2020Q4 us-gaap Property Subject To Or Available For Operating Lease Accumulated Depreciation
PropertySubjectToOrAvailableForOperatingLeaseAccumulatedDepreciation
1466000
CY2021Q4 us-gaap Property Subject To Or Available For Operating Lease Net
PropertySubjectToOrAvailableForOperatingLeaseNet
1643000
CY2020Q4 us-gaap Property Subject To Or Available For Operating Lease Net
PropertySubjectToOrAvailableForOperatingLeaseNet
1941000
CY2021 us-gaap Operating Leases Income Statement Depreciation Expense On Property Subject To Or Held For Lease
OperatingLeasesIncomeStatementDepreciationExpenseOnPropertySubjectToOrHeldForLease
442000
CY2020 us-gaap Operating Leases Income Statement Depreciation Expense On Property Subject To Or Held For Lease
OperatingLeasesIncomeStatementDepreciationExpenseOnPropertySubjectToOrHeldForLease
439000
CY2021 smlr Accumulated Depreciation Reduction For Returned Items
AccumulatedDepreciationReductionForReturnedItems
310000
CY2020 smlr Accumulated Depreciation Reduction For Returned Items
AccumulatedDepreciationReductionForReturnedItems
268000
CY2021 us-gaap Gain Loss On Sale Of Leased Assets Net Operating Leases
GainLossOnSaleOfLeasedAssetsNetOperatingLeases
-362000
CY2020 us-gaap Gain Loss On Sale Of Leased Assets Net Operating Leases
GainLossOnSaleOfLeasedAssetsNetOperatingLeases
-271000
CY2021Q4 smlr Assets For Lease Customer Location
AssetsForLeaseCustomerLocation
631000
CY2020Q4 smlr Assets For Lease Customer Location
AssetsForLeaseCustomerLocation
736000
CY2021Q4 us-gaap Inventory Net
InventoryNet
550000
CY2020Q4 us-gaap Inventory Net
InventoryNet
340000
CY2020Q3 smlr Payments To Purchase Inventory
PaymentsToPurchaseInventory
1202000
CY2020Q3 smlr Distribution Agreement Renewal Term
DistributionAgreementRenewalTerm
P4Y
CY2021 us-gaap Variable Lease Income
VariableLeaseIncome
21510000
CY2020 us-gaap Variable Lease Income
VariableLeaseIncome
11610000
CY2021 us-gaap Sales Type Lease Revenue
SalesTypeLeaseRevenue
956000
CY2020 us-gaap Sales Type Lease Revenue
SalesTypeLeaseRevenue
1250000
CY2021Q4 smlr Income Taxes Receivable Cares Act
IncomeTaxesReceivableCaresAct
1240000
CY2021Q4 us-gaap Property Plant And Equipment Excluding Lessor Asset Under Operating Lease Before Accumulated Depreciation
PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseBeforeAccumulatedDepreciation
882000
CY2020Q4 us-gaap Property Plant And Equipment Excluding Lessor Asset Under Operating Lease Before Accumulated Depreciation
PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseBeforeAccumulatedDepreciation
786000
CY2021Q4 us-gaap Property Plant And Equipment Excluding Lessor Asset Under Operating Lease Accumulated Depreciation
PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAccumulatedDepreciation
488000
CY2020Q4 us-gaap Property Plant And Equipment Excluding Lessor Asset Under Operating Lease Accumulated Depreciation
PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAccumulatedDepreciation
525000
CY2021Q4 us-gaap Property Plant And Equipment Excluding Lessor Asset Under Operating Lease After Accumulated Depreciation
PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAfterAccumulatedDepreciation
394000
CY2020Q4 us-gaap Property Plant And Equipment Excluding Lessor Asset Under Operating Lease After Accumulated Depreciation
PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAfterAccumulatedDepreciation
261000
CY2021 us-gaap Depreciation Excluding Lessor Asset Under Operating Lease
DepreciationExcludingLessorAssetUnderOperatingLease
180000
CY2020 us-gaap Depreciation Excluding Lessor Asset Under Operating Lease
DepreciationExcludingLessorAssetUnderOperatingLease
138000
CY2021Q4 us-gaap Long Term Investments
LongTermInvestments
821000
CY2020Q4 us-gaap Long Term Investments
LongTermInvestments
3051000
CY2020Q4 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
1942000
CY2020 us-gaap Debt And Equity Securities Gain Loss
DebtAndEquitySecuritiesGainLoss
442000
CY2021 us-gaap Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount
0
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
80000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
245000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1754000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1524000
CY2021Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
1159000
CY2020Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
861000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
523000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
413000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3436000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2798000
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
61000
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
61000
CY2020Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P61M
CY2021Q4 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P3Y9M
CY2021 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
false
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
112000
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
97000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
87000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
90000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
93000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
71000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
341000
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
16000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
325000
CY2021Q4 smlr Operating Lease Expenses In Excess Of Cash Payments
OperatingLeaseExpensesInExcessOfCashPayments
11000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
314000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
314000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 smlr Number Of Votes For Each Share
NumberOfVotesForEachShare
1
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
1433120
CY2020Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
1528295
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
1433120
CY2020Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
1528295
CY2020Q4 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
1942000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1581582
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.23
CY2019Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y10M9D
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
70827000
CY2020 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
130162
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.95
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1451420
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.25
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y10M28D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
131714000
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P3Y11M19D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
119830000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1420368
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.15
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y10M13D
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
129039000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1356245
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.30
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P3Y11M19D
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
119830000
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
0
CY2021 smlr Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested In Period Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedInPeriodGrantDateFairValue
192000
CY2020 smlr Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested In Period Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedInPeriodGrantDateFairValue
253000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
5516
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
95175
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.55
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1356245
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.30
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
641
CY2021 smlr Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantDateFairValue
557000
CY2020 smlr Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantDateFairValue
50000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
749000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
253000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
749000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
253000
CY2021 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
1397000
CY2020 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2021 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
428000
CY2020 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
343000
CY2020 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
2136000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2233000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2479000
CY2021 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
1825000
CY2020 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
343000
CY2021 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
456000
CY2020 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
2052000
CY2021 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-48000
CY2020 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
84000
CY2021 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
408000
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0155
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0219
CY2021 smlr Effective Income Tax Rate Reconciliation Deferred Tax Adjustments Percent
EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsPercent
0.0022
CY2020 smlr Effective Income Tax Rate Reconciliation Deferred Tax Adjustments Percent
EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsPercent
0.0073
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.1062
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.0844
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.0116
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.0044
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.0046
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.0000
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.1145
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.1504
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
446000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
492000
CY2021Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
220000
CY2020Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
233000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
556000
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
108000
CY2021Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
1946000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
529000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
209000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
228000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
818000
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
14000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
0
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
2070000
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
2473000
CY2021Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
49000
CY2020Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
12000
CY2021Q4 smlr Deferred Tax Assets Right Of Use Assets
DeferredTaxAssetsRightOfUseAssets
75000
CY2020Q4 smlr Deferred Tax Assets Right Of Use Assets
DeferredTaxAssetsRightOfUseAssets
96000
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
124000
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
18000
CY2021Q4 smlr Deferred Tax Assets Lease Liabilities
DeferredTaxAssetsLeaseLiabilities
77000
CY2020Q4 smlr Deferred Tax Assets Lease Liabilities
DeferredTaxAssetsLeaseLiabilities
98000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
2070000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
2473000
CY2020Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
2365000
CY2021Q4 us-gaap Tax Credit Carryforward Amount
TaxCreditCarryforwardAmount
0
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
476000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
341000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
341000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
295000
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
41000
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
1000
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
94000
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
45000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
476000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
341000
CY2020 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2021 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6731693
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
17222000
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.56
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6584441
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
14007000
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.13
CY2021 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
73767
CY2021 smlr Amount Of Dilutive Securities Common Stock Warrants
AmountOfDilutiveSecuritiesCommonStockWarrants
0
CY2021 smlr Adjustments Related To Common Stock Warrants Earnings Per Share
AdjustmentsRelatedToCommonStockWarrantsEarningsPerShare
0
CY2020 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
70281
CY2020 smlr Amount Of Dilutive Securities Common Stock Warrants
AmountOfDilutiveSecuritiesCommonStockWarrants
0
CY2021 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1333148
CY2021 us-gaap Amount Of Dilutive Securities Stock Options And Restrictive Stock Units
AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits
0
CY2021 smlr Adjustments Related To Common Stock Options Earnings Per Share
AdjustmentsRelatedToCommonStockOptionsEarningsPerShare
0
CY2020 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1411839
CY2020 us-gaap Amount Of Dilutive Securities Stock Options And Restrictive Stock Units
AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits
0
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8138608
CY2021 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
17222000
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.12
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8066561
CY2020 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
14007000
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.74

Files In Submission

Name View Source Status
0001554859-22-000008-index-headers.html Edgar Link pending
0001554859-22-000008-index.html Edgar Link pending
0001554859-22-000008.txt Edgar Link pending
0001554859-22-000008-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
smlr-20211231.xsd Edgar Link pending
smlr-20211231ex231b884c8.htm Edgar Link pending
smlr-20211231ex311705afc.htm Edgar Link pending
smlr-20211231ex3122a4da0.htm Edgar Link pending
smlr-20211231ex32109db16.htm Edgar Link pending
smlr-20211231ex3228385c1.htm Edgar Link pending
smlr-20211231ex423d89fdf.htm Edgar Link pending
smlr-20211231x10k.htm Edgar Link pending
smlr-20211231x10k006.jpg Edgar Link pending
smlr-20211231x10k_htm.xml Edgar Link completed
smlr-20211231_cal.xml Edgar Link unprocessable
smlr-20211231_def.xml Edgar Link unprocessable
smlr-20211231_lab.xml Edgar Link unprocessable
smlr-20211231_pre.xml Edgar Link unprocessable